The UPS board of directors on Thursday, Aug. 11, named Dr. Candace Kendle, an expert in the biopharmaceutical industry, a company director effective immediately. Kendle’s appointment to the post expands the UPS board to 12 members. She will serve on the Audit Committee and will stand for election to a regular one-year term at UPS’s annual shareowners’ meeting in May 2012.
Kendle, 64, is the co-founder and former chairman and chief executive officer of Kendle International Inc., a global clinical research organization that delivers a wide range of clinical development and clinical trial services to biopharmaceutical companies around the world. Headquartered in Cincinnati, the company was acquired last month by INC Research of Raleigh, N.C., for $232 million.
Kendle is a founding member and past chairperson of the Association of Clinical Research Organizations and is recognized in the clinical research industry. Prior to founding Kendle International, she held senior faculty positions at the University of North Carolina Schools of Pharmacy and Medicine, the University of Pennsylvania School of Medicine, the University of Cincinnati College of Pharmacy and the Philadelphia College of Pharmacy and Science.
Kendle is a member of the Committee of 200, an organization of preeminent women entrepreneurs and corporate leaders, and serves as a mentor for the Fortune-U.S. State Department Global Women Leaders Mentoring Partnership. For more than 10 years, she has served on the H.J. Heinz Co. board, where she sits on the Audit and Management Development & Compensation Committees.
Kendle joins the board at a time when UPS has made healthcare logistics one of its most important strategic priorities. With the addition of new facilities earlier this year in Singapore, the Netherlands, Canada, Latin America and the United States, UPS now operates 30 global healthcare facilities in strategic locations around the globe with more than 4 million square feet of dedicated healthcare distribution space.
